Onasemnogene abeparvovec

Onasemnogene abeparvovec is designated as an orphan drug by the US FDA on 9/30/2014, used in treatment of spinal muscular atrophy, manufactured / distributed by AveXis, Inc

How does this medication work?

ZOLGENSMA is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

What are the limitations of use with this medication?

• The safety and effectiveness of repeat administration of ZOLGENSMA have not been evaluated.
• The use of ZOLGENSMA in patients with advanced SMA (e.g., complete paralysis of limbs, permanent ventilator dependence) has not been evaluated.

How is this medication supplied?

• ZOLGENSMA is for single-dose intravenous infusion only.
• ZOLGENSMA is a suspension for intravenous infusion, supplied as single-use vials.
• ZOLGENSMA is provided in a kit containing 2 to 9 vials, as a combination of 2 vial fill volumes (either 5.5 mL or 8.3 mL). All vials have a nominal concentration of 2.0 × 1013 vector genomes (vg) per mL. Each vial of ZOLGENSMA contains an extractable volume of not less than either 5.5 mL or 8.3 mL.

How should this medication be used?

• The recommended dosage of ZOLGENSMA is 1.1 × 1014 vector genomes (vg) per kg of body weight.
• Administer ZOLGENSMA as an intravenous infusion over 60 minutes.
• Starting one day prior to ZOLGENSMA infusion, administer systemic corticosteroids equivalent to oral prednisolone at 1 mg/kg of body weight per day for a total of 30 days.

What tests are done to monitor treatment?

• At the end of the 30-day period of systemic corticosteroid treatment, check liver function by clinical examination and by laboratory testing.
• For patients with unremarkable findings, taper the corticosteroid dose over the next 28 days. If liver function abnormalities persist, continue systemic corticosteroids (equivalent to oral prednisolone at 1 mg/kg/day) until findings become unremarkable, and then taper the corticosteroid dose over the next 28 days.
• Consult expert(s) if patients do not respond adequately to the equivalent of 1 mg/kg/day oral prednisolone.

Who should not use this medication (contraindications)?

None.

How much does this medication cost?

Novartis' Zolgensma, a one-time gene therapy for spinal muscular atrophy tops the list with a price tag of $2.125 million and is one of the most expensive medications for a single dose.

What should be watched monitored during the treatment?

• Thrombocytopenia: Monitor platelet counts before ZOLGENSMA infusion, and weekly for the first month and then every other week for the second and third month until platelet counts return to baseline.
• Thrombotic Microangiopathy (TMA): If clinical signs, symptoms and/or laboratory findings occur, consult a pediatric hematologist and/or pediatric nephrologist immediately to manage as clinically indicated.
• Elevated Troponin-I: Monitor troponin-I before ZOLGENSMA infusion, and weekly for the first month and then monthly for the second and third month until troponin-I level returns to baseline.

What are the side effects of this medication?

• The most common adverse reactions (incidence ≥ 5%) were elevated aminotransferases and vomiting.

What are the drug interactions I should be aware of?

• Where feasible, adjust a patient’s vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ZOLGENSMA infusion.

Can this medication be used in children?

• Pediatric Use: Use of ZOLGENSMA in premature neonates before reaching full term gestational age is not recommended because concomitant treatment with corticosteroids may adversely affect neurological development.
• Delay ZOLGENSMA infusion until full-term gestational age is reached.

• Dailymed label info on Onasemnogene abeparvovec
• FDA Onasemnogene abeparvovec

Onasemnogene abeparvovec Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

Resources

Frequently asked questions

‎

‎